Latest James Heywood Stories
CAMBRIDGE, Mass., May 2, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that it has added two members to its board of directors: Robert Sepucha Jr. and Michael M. Smith. The Institute's board grows to include 14 members with deep ties to the ALS community, academic research, philanthropy and pharmaceutical development. (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO) Robert Sepucha Jr. is senior vice president, policy...
LEXINGTON, Mass., April 24, 2013 /PRNewswire-USNewswire/ -- The ninth annual "The Cure is Coming!" 5k and awareness walk to end ALS will be held on Saturday, May 4, 2013 in Lexington, MA. The event will gather local area residents to run, walk, or roll to raise money and awareness for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. All proceeds will benefit research efforts at the Cambridge, MA-based nonprofit biotech, the ALS Therapy Development Institute...
CAMBRIDGE, Mass., April 23, 2013 /PRNewswire-USNewswire/ -- In recognition of people under 30 years old affected by amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, the ALS Therapy Development Institute (ALS TDI) announced today that it has appointed representatives to lead the Young Faces of ALS (YFALS) campaign this year. (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO) The YFALS program is driven by several ALS patients diagnosed with the...
Industry and Patient Groups Join Forces to Form an Alliance to Accelerate Drug Development CAMBRIDGE, Mass., March 4, 2013 /PRNewswire/ -- GNS Healthcare today announced that it has joined in the formation of Orion Bionetworks. This unique alliance will work to transform our understanding of and accelerate the drug development process for a wide variety of diseases, beginning with multiple sclerosis (MS). Using patient data from alliance members Accelerated Cure Project for Multiple...
CAMBRIDGE, Mass., Feb. 11, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that it has received FDA approval to conduct a clinical trial of TDI-132 (aka: fingolimod, Gilenya(TM)) in ALS. Fingolimod is currently being marketed by Novartis AG as Gilenya(TM) as a treatment for some forms of multiple sclerosis. This clinical trial is being launched as a Phase IIA with the primary purpose of determining the safety and tolerability of...
Institutes to Share Resources to Identify Potential Compounds Targeting TDP-43 Form of ALS CAMBRIDGE, MA and SAN FRANCISCO, Dec. 4, 2012 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) and the Gladstone Institutes today announced the formation of a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process. (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO) "We are thrilled...
Academic, Biotech and Philanthropic Innovators Meet for 8(th) Annual Summit CAMBRIDGE, Mass., Sept. 5, 2012 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) is holding its 8(th) annual Leadership Summit on Thursday, November 1, 2012 at the Sheraton Hotel in Boston. The free event aims to illuminate the latest trends in preclinical and clinical research for neurodegeneration and the converging roles of the patient, foundation and pharmaceutical company....
Partnership Aimed at Neuromuscular Junction Strength against Disease Course CAMBRIDGE, Mass. and SCHLIEREN-ZURICH, Switzerland, May 14, 2012 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into collaboration with Neurotune to investigate a potential treatment for ALS (aka Motor Neuron or Lou Gehrig's disease). (Photo: http://photos.prnewswire.com/prnh/20120514/DC05793) (Logo:...
The annual three day, 270 mile bike ride continues its commitment to fund research to end ALS CAMBRIDGE, Mass., April 23, 2012 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) Tri-State Trek is celebrating its 10th anniversary this year. A three-day, 270 mile bike ride from Boston to Greenwich, CT, the Trek raises money and awareness to end amyotrophic lateral sclerosis (ALS), better known as Lou Gehrig's disease. (Logo:...
Tournament Proceeds to Benefit Research into Treatments for ALS, Lou Gehrig's Disease CAMBRIDGE, Mass., April 2, 2012 /PRNewswire-USNewswire/ -- The Young Faces of ALS Campaign (YFALS) announced its second annual "National Corntoss Challenge" fundraising event occurring in multiple cities this May and June in support of research toward an effective treatment for ALS, better known as Lou Gehrig's disease. This is a charity tournament where thousands of participants in cities from...
